Regenerative Medicine Market

Regenerative Medicine Market Overview 2030:

The global regenerative medicine market size was valued at $10,107.32 million in 2020, and is estimated to reach $83,196.72 million by 2030, growing at a CAGR of 23.4% from 2021 to 2030. Regenerative medicine is an emerging field that aims to repair and replace damaged organs and tissues. It is potential for the treatment of chronic diseases and disorders, such as Alzheimer disease, diabetes, and others. 

Cell therapy involves the use of cellular materials such as stem cells, autologous cells, xenogeneic cells, and others, for the therapeutic treatment of patients. Cell therapy is used to replace damaged cells, deliver therapies to target tissues/organs, stimulate self-healing, and other applications in the regenerative medicine market. Gene therapy involves the therapeutic delivery of nucleic acid polymers or genes into a patient's cells to treat or prevent diseases.

The growth in number of diseases, such as congestive heart failure, myocardial infarction, Parkinson’s disease, varied forms of bone loss, and Duchenne muscular dystrophy (DMD), increase the demand for cell therapy in the regenerative medicine market. Moreover, reconstruction of bladder, ureter and urethra has been conventionally dependent on the use of heterotopic autologous grafts, such as intestine, colon, or stomach, which drives the market growth. Many companies are attempting to boost the advancement in cell therapy by either collaborating with other companies or research institutes. For instance, in April 2018, Eli Lilly collaborated with Sigilon Therapeutics to develop encapsulated cell therapies. These therapies are used for type I diabetes treatment. The development of such advanced products helps to increase the demand for cell therapies, which is expected to boost the regenerative medicine market.

Cell therapies, such as autologous cell therapy, allogenic cell therapy, and xenogenic cell therapy are widely used in the regenerative medicine market. However, fewer products have received FDA approval for commercialization in the market. Laviv from Fibrocell Science, Inc. is used for the treatment of moderate-to-severe nasolabial fold wrinkles in adults. Carticel from Genzyme Corporation is used for repair of symptomatic cartilage defects of knees.

In addition, the emergence of new technologies, such as 3-D printing is expected to increase the adoption of autologous cell therapies for life threatening diseases. Apligraf from Organogenesis, Inc. is one such allogenic cell-based product used in the treatment of venous leg ulcers and diabetic foot ulcers.

Advancement in regenerative technologies fuels the commercial applications of stem cells in the regenerative medicine market. Some of the promising organs are heart arteries, engineered bladders, and other internal organs & ligaments. Few stem cell-based therapies are under clinical trials, which exhibit tremendous potential for use in tissue regeneration. Market players have introduced several technologies for the development of stem cell therapies to increase the efficiency of stem cell research and commercial applications. These developmental activities drive the growth of the regenerative medicine market. Several programs and investment by governments and private agencies to support R&D are expected to enhance the market growth during the forecast period. However, the high cost of treatment of regenerative medicine is expected to hinder the market growth during the forecast period.

GlaxoSmithKline has developed a product for adenosine deaminase, which causes severe combined immunodeficiency (ADA-SCID). In addition, other companies that are working on R&D of gene additive therapies include, GE Healthcare, Mayo Clinic, and others. The research involves the use of nucleases zinc finger nucleases (ZFNs), CRISPR/Cas9, mega nucleases (MNs) and others, which are customized to effectively modify human genome by targeting specific cells. However, there are unwanted effects of gene correction resulting in manipulation of cells, which impacts the development and proliferation of these cells. However, varying levels of efficiency, which depends on the genome of the targeted cells constrain the usage of gene correction treatment. 

Impact Of Covid-19 On Regenerative Medicine Market

The COVID-19 outbreak is anticipated to have a positive impact on the global regenerative medicine market. For instance, in 2020, Singapore based Duke-NUS medical school’s emerging infectious disease program demonstrated the utility of immunotherapies in the treatment of COVID-19. 

Regenerative Medicine Market Segmentation

The regenerative medicine market is segmented on the basis of product type, material, application, and region. By type, the market is categorized into cell therapy, gene therapy, tissue engineering, and small molecule & biologic. 

Depending on material, the market is categorized into synthetic material, biologically derived material, genetically engineered material, and pharmaceutical. Synthetic material is further divided into biodegradable synthetic polymer, scaffold, artificial vascular graft material, and hydrogel material. Biologically derived material is further bifurcated into collagen and xenogenic material. Genetically engineered material is further segmented into deoxyribonucleic acid, transfection vector, genetically manipulated cell, three-dimensional polymer technology. Transgenic divided into fibroblast, neural stem cell, and gene-activated matrices. Pharmaceutical is further divided into small molecule and biologic. By application, the market is categorized into cardiovascular, oncology, dermatology, musculoskeletal, wound healing, ophthalmology, neurology, and others.

Segment Review

Depending on product type, the cell therapy segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to increase in advancement in new technologies and rise in availability of the regenerative medicine products. However, the gene therapy segment is expected to witness considerable growth during the forecast period, owing to increase in prevalence of chronic diseases.

By application, the musculoskeletal segment was the major contributor in 2020, and is expected to maintain its lead during the forecast period, owing to increase in prevalence of genetic disorders. However, dermatology are also anticipated to witness growth due to presence of strong product pipeline.

By material, the Biologically derived Materials segment was the major contributor in 2020, and is expected to maintain its lead during the forecast period, owing to increase in demand for organ transplantation. However, Pharmaceuticals are anticipated to witness growth due to presence of strong product pipeline.

Key Benefits For Stakeholders

• The study provides an in-depth analysis of the regenerative medicine market, and the current trends & future estimations to elucidate imminent investment pockets.
• It presents a quantitative analysis of the market from 2021 to 2030 to enable stakeholders to capitalize on the prevailing regenerative medicine market opportunities.
• Extensive analysis of the market based on procedures and services assists to understand the trends in the industry.
• Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the regenerative medicine market.

 Regenerative Medicine Market Report Highlights